Guillermo Garcia-Manero, MD, highlights recent shifts in the lower-risk myelodysplastic syndrome treatment paradigm.
Back
Dissecting Pivotal Research in Lower-Risk MDS, From ASCO 2025
Guillermo Garcia-Manero, MD, details key updates in lower-risk myelodysplastic syndrome around the 2025 ASCO Annual Meeting.
Dissecting Pivotal Research in Lower-Risk MDS, From ASCO 2025
Episodes
All
All
Guillermo Garcia-Manero, MD, discusses OS data from the COMMANDS trial for luspatercept in ESA-naive, lower-risk MDS.
Guillermo Garcia-Manero, MD, highlights clinical trial findings and real-world data for luspatercept in ESA-naive, lower-risk MDS.
Guillermo Garcia-Manero, MD, discusses the integration of luspatercept into real-world practice in ESA-naive, lower-risk MDS.
Guillermo Garcia-Manero, MD, discusses second-line treatment decision-making in lower-risk MDS.
Guillermo Garcia-Manero, MD, discusses ongoing research to watch in MDS.
Advertisement
Advertisement
Trending on OncLive
1
Docetaxel Remains Unbeaten in Immunotherapy-Refractory NSCLC
2
Long-Term Data Refine the Role of Immunotherapy Across Early-Stage NSCLC Settings
3
Ris-Rez Meets Phase 3 Efficacy End Point for R/R Osteosarcoma
4
Dr Tarantino on the Evolution of TROP2-Directed ADCs in First-Line TNBC
5